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A key aspect to finding an efficacious human immunodeficiency virus (HIV) vaccine is 
the optimization of vaccine schedules that can mediate the efficient maturation of pro-
tective immune responses. In the present study, we investigated the effect of alternate 
booster regimens on the immune responses to a candidate HIV-1 clade C CN54gp140 
envelope protein, which was coadministered with the TLR4-agonist glucopyranosyl 
lipid A-aqueous formulation. Twelve study participants received a common three-dose 
intramuscular priming series followed by a final booster at either 6 or 12 months. The 
two homologous prime-boost regimens were well tolerated and induced CN54gp140-
specific responses that were observed in both the systemic and mucosal compart-
ments. Levels of vaccine-induced IgG-subclass antibodies correlated significantly with 
FcγR engagement, and both vaccine regimens were associated with strikingly similar 
patterns in antibody titer and FcγR-binding profiles. In both groups, identical changes in 
the antigen (Ag)-specific IgG-subclass fingerprint, leading to a decrease in IgG1 and an 
increase in IgG4 levels, were modulated by booster injections. Here, the dissection of 
immune profiles further supports the notion that prime-boost strategies are essential for 
the induction of diverse Ag-specific HIV-1 responses. The results reported here clearly 
demonstrate that identical responses were effectively and safely induced by both vac-
cine regimens, indicating that an accelerated 6-month regimen could be employed for 
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the rapid induction of immune responses against CN54gp140 with no apparent impact 
on the overall quality of the induced immune response. (This study has been registered 
at http://ClinicalTrials.gov under registration no. NCT01966900.)
Keywords: igG subclasses, vaccine interval, human immunodeficiency virus vaccine, adjuvant, homologous 
prime-boost strategy, human immunodeficiency virus envelope protein, mucosal compartment
inTrODUCTiOn
The human immunodeficiency virus (HIV) continues to infect 
nearly two million people every year with one million AIDS-
related deaths occurring annually (1). A critical step toward the 
effective control of the HIV epidemic is the development of an 
efficacious HIV vaccine, but despite concerted efforts spanning 
over 30 years, an effective AIDS vaccine remains elusive (2, 3).
Two phase III trials (VAX 004/003), using monomeric 
AIDSVAX clade B/E gp120 proteins as immunogens, failed to 
show efficacy in reducing HIV acquisition (4, 5), despite induc-
tion of high antibody binding titers following an autologous 
prime-boost regime. In contrast, the Thai phase III vaccine regi-
men (RV144), comprising two priming injections of a recombi-
nant canarypox vector vaccine (ALVAC-HIV) followed by two 
booster injections of ALVAC-HIV combined with a recombinant 
gp120 subunit vaccine (AIDSVAX B/E), demonstrated a modest 
efficacy of 31.2% against HIV acquisition at 42 months after vac-
cination (6). Notably, IgG antibodies against the variable regions 
1 and 2 (V1–V2) of HIV-1 envelope proteins correlated with a 
decreased risk of HIV acquisition (7) and post  hoc analysis of 
RV144 estimated efficacy at 6  months after vaccination to be 
60.5%, indicating an early protective vaccine effect that declines 
over time (8).
More recent evidence suggests that antigen (Ag)-specific 
immunoglobulin (Ig) diversification (9) may represent another 
important criterion for preventing HIV infection. An immune-
correlates analysis of the RV144 trial identified that vaccine-
induced Env V1–V2 IgG3 levels correlated with a decreased 
risk of HIV-1 infection and declined in line with the observed 
vaccine efficacy (10). It has long been recognized that different 
IgG subclasses (IgG1–4) have different effector functions, both in 
terms of triggering FcγR-expressing cells, resulting in antibody-
dependent cellular phagocytosis (ADCP) or antibody-dependent 
cell-mediated cytotoxicity (ADCC), and activating complement. 
IgG1, IgG3, and IgG4 are commonly associated with B  cell-
mediated responses to protein Ags, while heavily glycosylated 
Ags are often associated with IgG2 responses (11). Correlation of 
V1–V2 IgG3 levels with reduced risk of acquisition in the RV144 
trial has driven interest in the induction of IgG3 antibodies. IgG3 
is characterized by an elongated hinge region of up to 62 amino 
acids (11) and has been associated with high Fc gamma receptor 
(FcγR) binding of IgG3 immune complexes (12). Furthermore, 
the extended hinge region equips IgG3 with a high degree of 
conformational flexibility, suggesting an improved potential for 
penetrating the protective HIV glycan shield, which could be 
crucial for preventing HIV immune evasion.
Although encouraging, the modest and transient efficacy 
observed in RV144 trial highlights the need for greater 
understanding of the parameters modulating the serological 
fingerprint of vaccine-induced HIV antibodies and their capacity 
for driving Fc-mediated effector functions, such as ADCC and 
ADCP, following vaccination (13, 14). While ADCC is associated 
with the crosslinking of FcγRIIIa (CD16a), ADCP is mediated 
primarily through FcγRIIa (CD32a). These known interactions 
provide the framework for a recently published assay, utilizing 
FcγR ectodomain dimers to probe for Fc-dependent functions 
(15, 16).
In addition to the HIV immunogen (vaccine vector and 
vaccine dosage) and choice of adjuvant, the effective induction 
of desired immune responses against HIV can be critically 
influenced by the timing and interval between prime and boost 
immunizations (IMs) (17). Primary Ag challenge has been shown 
to lead to the activation of naïve B cells, but more importantly to 
the generation of a memory B cell (mBC) pool that is vital for the 
secretion of class switched and high-affinity antibodies following 
Ag rechallenge (18). Upon reexposure to Ag mBC can rapidly 
differentiate into antibody secreting plasmablasts and plasma 
cells and thereby promote protective and long-lasting immune 
responses (19, 20). The timing of sequential IMs is thought to 
modulate the interplay between T and B  cells influencing the 
quality and durability of induced humoral responses (21). The 
development of HIV antibodies with a high degree of somatic 
hypermutation requires Ag-specific B cells to repeatedly circulate 
between the light and dark zone of the germinal center (GC), a 
process driven by cognate CD4 T helper follicular (Tfh) cells and 
induction of appropriate cytokines and growth factors (20, 22, 23). 
The mechanisms underlying CD4 Tfh cell memory responses are 
poorly defined, and while expression of cognate Ag on B cells is 
thought essential at the peak of effector generation (24), longer 
term persistence beyond the expansion phase can lead to reduced 
memory functionality (25). Thus, effective generation of CD4 Tfh 
memory is likely Ag dose and time dependent, where revaccina-
tion before full contraction of the effector response may negatively 
impact on the boosting response. Therefore, understanding the 
time dependent impact of vaccination on the quality and durabil-
ity of induced B and CD4 T cell responses may prove essential for 
the rational design of optimal homologous and/or heterologous 
prime-boost regimens against HIV.
To facilitate the rapid evaluation of prospective HIV vac-
cine regimens, small scale phase I clinical trials can be utilized 
to qualitatively and quantitatively measure vaccine-mediated 
humoral and T cell immune responses (17). The current homolo-
gous prime-boost study was designed to dissect the effect of a 
standard (6  months) versus delayed (12 month) boost on the 
quality of induced antibody response to a candidate HIV-1 enve-
lope protein CN54gp140, coadministered with the TLR4-agonist 
glucopyranosyl lipid A-aqueous formulation (GLA-AF).
TaBle 1 | Vaccine dosage and study schema.
Group N Vaccine dosagea Vaccine given at months
0 1 2 6 12
A 6 CN54gp140 + GLA-AF + + + + −
B 6 CN54gp140 + GLA-AF + + + − +
aVaccines: recombinant uncleaved clade C HIV-1 envelope gp140 protein 
(CN54gp140) administered intramuscularly into the deltoid muscle of the upper arm at 
a dosage of 100 µg CN54gp140 formulated with 5 µg glucopyranosyl lipid A-aqueous 
formulation in a total volume of 0.4 ml.
3
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MaTerialS anD MeTHODS
ethical and regulatory approvals
The trial proposal, the trial-specific information provided to 
volunteers, the consent form and substantial protocol amend-
ments (if applicable) were reviewed by a recognized Research 
Ethics Committee and by the Medicines and Healthcare products 
Regulatory Authority.
Conduct of the Study
The study was conducted in compliance with UK Clinical Trial 
Regulations and any amendments, which include compliance 
with the principles of good clinical practice, and the study abided 
by the principles of the Declaration of Helsinki.
Volunteer information and Consent
All volunteers provided written informed consent to participate 
in the trial on the basis of appropriate information and with 
adequate time to consider the information and discuss the trial 
with the principal investigator or her delegate. Participants were 
asked to explain what the trial involved in their own words, to 
ensure the volunteer understood the intensity of the schedule and 
the issues associated with taking part in a trial of a candidate HIV 
vaccine. All volunteers were made aware that they were free to 
withdraw without obligation at any time and that such an action 
would not adversely affect any aspect of their medical care or legal 
rights.
Study Vaccines
A recombinant uncleaved clade C HIV-1 envelope gp140 protein 
(CN54gp140) produced by Polymun Scientific (Klosterneuburg, 
Austria) to GMP specification, which has previously been 
reported to be immunogenic in a number of preclinical and 
clinical studies (26, 27), was used for the X001 clinical trial. 
The vaccine Ag CN54gp140 was administered intramuscularly 
into the deltoid muscle of the upper arm at a dosage of 100 µg 
CN54gp140 formulated with 5 µg GLA-AF [Infectious Disease 
Research Institute, Seattle, WA, USA (28)] in a total volume of 
0.4 ml. GLA has been shown to enhance antibody responses in 
mice, non-human primates, and humans without causing adverse 
reactions (29, 30). Good adjuvanticity was observed in a previous 
influenza clinical trial where they used 2.5 µg GLA and a clinical 
trial of a leishmaniasis vaccine using 2 or 5 µg GLA in an oil- 
in-water emulsion formulation (GLA-SE), which was safe and well 
tolerated (30, 31). Since much of the reactogenicity of GLA-SE 
is believed to be associated with its oil-in-water form, the aque-
ous formulation GLA-AF was assumed to be less reactogenic. 
Subsequent animal studies revealed that GLA-AF has broadly 
equivalent adjuvant activity to GLA-SE and based on these 
findings for the current trial a 5-µg dose of GLA was selected 
(32). Further, good tolerability of GLA-AF at a dose of 5 µg in 
combination with the CN54gp140 Ag has been demonstrated in 
previous clinical trials conducted by us (27, 33).
Trial Participants and randomization
The trial was open labeled without placebo control, and we sought 
to enroll 12 healthy volunteers, male or female between the ages 18 
and 45 who did not report high-risk behavior for HIV infection. 
They were randomly assigned to two groups of six each within a 
screening period of 42 days prior to the first vaccination. Trial 
participants were required to follow a rigorous visit schedule and 
depending on the study group underwent up to 17 blood draws 
(Tables S6 and S7 in Supplementary Material).
iM and Sampling
Study participants in each group received three injections (prim-
ing phase) followed by a booster IM at 6 months (Group A) or 
12 months (Group B) of the study vaccine CN54gp140 formulated 
with GLA-AF. The study schema is detailed in Table  1. Blood 
samples and mucosal secretions (cervicovaginal, urethral, rectal, 
and seminal) were collected at designated time points (Tables 
S6 and S7 in Supplementary Material) for immunogenicity and 
vaccine safety analysis.
Primary and Secondary Outcomes
The primary endpoint was to evaluate the safety and tolerability 
of two vaccine regimens consisting of three initial injections of 
CN54gp140 (priming phase) at a dosage of 100  µg formulated 
with 5  µg GLA-AF and a final booster injection at 6  months 
(Group A) or 12 months (Group B). The secondary outcome was 
to assess B and T cell-mediated and antibody binding responses 
in the peripheral blood.
Safety assessments and Monitoring
Collected data were identified only by a volunteer identification 
number. Safety and tolerability were addressed by examining 
the overall rates of solicited and unsolicited adverse events and 
serious adverse events that were potentially associated with vac-
cination and the number of volunteers who experienced these 
events. All clinical and routine laboratory work was included in 
the safety analysis (Tables S1 and S2 and Figures S1 and S2 in 
Supplementary Material).
HiV Testing
Study staff performed HIV testing and any associated pre- or 
posttest counseling, according to national guidelines at time 
points defined in the Schedules of Procedures (Tables S6 and S7 
in Supplementary Material).
Mucosal Secretion Collection
Cervicovaginal secretions were collected from female volunteers 
using the INSTEAD™ Softcup, a commercially available, self-
inserted menstrual cup made of polyethylene. There is a risk 
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of dislodging an intrauterine device (IUD) when removing the 
Softcup and women who have had toxic shock syndrome (TSS) 
should not use internal sanitary protection products. For these 
reasons, women with IUDs or a history of TSS were excluded 
from the study.
Urethral secretions were collected from male volunteers using 
a 2-mm diameter polyvinyl alcohol (PVA) sponge. Sponges could 
be self-inserted following explanation or were inserted by the 
clinical trials team at the NIHR/Wellcome Trust Imperial Clinical 
Research Facility at Hammersmith Hospital.
Rectal secretions were collected from male and female volun-
teers using a pre-moisturized (with 50 µl PBS) sponge.
Semen samples were either donated while within the ICRF 
or brought into the facility following donation at home (within 
3 h of ejaculation). Participants were instructed to donate semen 
following 24 h of sexual abstinence.
Mucosal secretion collection occurred at the time points 
indicated in the Schedules of Procedures (Tables S6 and S7 in 
Supplementary Material), except at visits when female volunteers 
were menstruating, in which case cervicovaginal secretions were 
not collected.
PePTiDe arraY analYSiS OF  
env-SPeCiFiC igG reSPOnSeS
Microarrays were designed to cover recently transmitted global 
HIV strains and currently used vaccines, therefore including 
gp140 sequences from eight recently transmitted virus isolates 
(subtypes A, C, B, CRF01_AE and CRF02_AG), plus additional 
peptide variants for previously identified hot spots of IgG rec-
ognition as well as CN54gp140 and MVA-CMDR encoded Env 
immunogens (Ahmed et al., manuscript in preparation).1 Each 
of the overlapping 15mer peptides on the array is present in 
triplicate.
Analysis of serum on the peptide microarrays was carried 
out according to the manufacturer’s instructions with minor 
modifications (www.jpt.com). After initial blocking (10  min 
with T20-blocking buffer, Thermo Fisher), slides were incubated 
with diluted serum samples (1:100 in T20) for 2  h at RT with 
gentle shaking. Slides were washed five times with TBS-T (0.5% 
Tween20), and bound antibodies were detected with a mouse 
antihuman-IgG Dylight649 (JPT) secondary antibody (1:5,000 
in T20) for 1 h at RT. After repeated washing, slides were dried 
and subsequently scanned on a GenePix 4000A scanner at 650 
and 532 nm. Samples of each vaccine (T0—baseline, T1—14-day 
post third IM, and T3—14-day post fourth IM) were processed 
simultaneously.
Analysis and mapping was performed using GenePix Pro 6.0 
(Molecular Devices) and R (ZZ). IgG responses against individual 
peptides were considered positive if the corresponding triplicate 
fluorescence intensity value was above 2,500 after subtraction of 
the pre-vaccination value in at least 25% of all vaccines.
1 Ahmed et al. Dissecting the dynamics of the envelope-specific IgG response over 
2 years of HIV infection. (Manuscript in preparation).
Processing of Mucosal Samples
Prior to processing the mucosal samples, the extraction buffer 
(EB) was prepared by adding 1  ml of 100× protease inhibitor 
cocktail set (Calbiochem, 539131) and 10% NaN3 (Sigma-Aldrich, 
S2002-25G, UK) to 100 ml sterile PBS.
Prior to analysis, Softcups containing cervicovaginal secre-
tions in 50 ml tubes were removed from −80°C, allowed to thaw 
on ice overnight, and centrifuged at 400 × g for 15 min at 4°C. An 
equal volume of EB was added to the secretion samples, mixed 
and aliquoted.
The 2-mm diameter PVA sponge used for the collection of 
urethral samples, and 500  µl EB was added to the top cham-
ber of a Costar Spin-X tube (Corning) and centrifuged for 
15  min at 13,000  rpm and 4°C. The eluate was collected and 
aliquoted.
Tubes containing the rectal swabs were removed from −80°C, 
thawed on wet ice, and placed into a 50  ml tube containing a 
sterile falcon filter unit (70  µm). To each tube, 500  µl EB was 
added before centrifugation at 400 ×  g for 10  min at 4°C. To 
remove debris, the eluate was transferred into the top chamber 
of a Spin-X tube, centrifuged at 13,000 rpm for min at 4°C, and 
aliquoted.
Seminal secretions were transferred into one or two sterile, 
plastic, 2  ml microcentrifuge tubes before centrifugation at 
1,200 × g, for 10 min, at 4°C. The supernatant (seminal plasma) 
was transferred into 2–3 prelabeled, sterile, plastic, 2 ml micro-
centrifuge tubes. All mucosal sample aliquots were frozen at 
−80°C until analysis via ELISA.
Peripheral Blood Mononuclear Cell 
(PBMC) Sample Preparation
Peripheral blood mononuclear cells were isolated using density 
gradient separation from heparinized whole blood, used fresh or 
frozen (within 8 h of blood collection) in a mixture of fetal bovine 
serum (Sigma-Aldrich, St. Louis, MO, USA) and DMSO at a 
90:10 ratio using a Kryo 560-16 rate controlled freezer (Planer, 
Sunbury-On-Thames, UK). PBMCs were stored in vapor phase 
liquid nitrogen at the IAVI Human Immunology Laboratory or 
St Mary’s Campus, Imperial College London.
HiV-Specific Binding antibodies—eliSa 
Platform
An extensive ELISA platform was developed and employed to 
measure both total and Ag-specific antibody responses in human 
plasma/serum samples and mucosal secretions. The protocols of 
the various Ig ELISAs are detailed in the Supplementary Material 
(Table S4 in Supplementary Material). In brief, Ag-specific 
gp140-binding antibodies were measured using a standardized 
ELISA platform. In plasma/serum samples Ag-specific IgA, IgM, 
IgG (total), and IgG subclasses were measured, while both total 
and Ag-specific IgA/G antibody responses were measured in the 
mucosal compartment (cervicovaginal, urethral, seminal, and 
rectal). A total of 96-well high binding MaxiSorp plates (Nunc) 
were coated with 50 μl/well recombinant CN54gp140 (Polymun 
Scientific) at 2.5 µg/ml in PBS for overnight at 4°C. As reference 
material, we used standard Igs (Table S4 in Supplementary 
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Material), which were captured with a combination of antihu-
man kappa and lambda light chain specific mouse antibodies. 
These capture antibodies were coated onto the plates overnight 
at 4°C, and coated plates were washed four times with PBS-T 
before blocking with the appropriate assay buffer (Table S4 in 
Supplementary Material). Following further washing, diluted 
sera or mucosal samples were added to the Ag-coated wells and 
titrations of Ig standards were added to the kappa/lambda capture 
antibody coated wells at 50 μl/well and incubated for 1 h at 37°C. 
Plates were washed four times prior to the addition of secondary 
antibody and incubated for 1 h at 37°C. Plates were washed four 
times and developed with 50 μl/well of KPL SureBlue TMB sub-
strate (Insight Biotechnology, UK). The detection of Ag-specific 
IgA/G in mucosal samples and the detection of Ag-specific 
IgA/M/G2 required a streptavidin-(poly)-HRP amplification 
step prior to TMB development (Table S4 in Supplementary 
Material). The reaction was stopped after 5 min by adding 50 μl/
well of 1 M H2SO4, and the absorbance read at 450 nm on a KC4 
spectrophotometer.
iFn-γ T Cell eliSpot assay
Cellular immunogenicity was assessed by IFN-γ T cell ELISpot 
using frozen PBMC. Prior to use, ELISpot plates, pre-coated 
with anti-IFN-γ antibody (Mabtech), were washed with PBS and 
blocked with RPMI supplemented with 10% heat-inactivated 
fetal calf serum (R10) for a minimum of 2 h at 37°C. PBMCs 
were plated out at 2 × 105 cells/well in 50 µl. For CN54gp140-
specific responses, two pools of 15mer peptides with 11 amino 
acid overlap (P1 and P2) matched to the HIV-1 sequence vaccine 
insert were plated in quadruplicate wells. Peptides were initially 
dissolved and pooled in DMSO before dilution in R10 with final 
assay DMSO concentration of 0.45% v/v. Eight negative no-pep-
tide control wells were cultured in R10 supplemented with 0.45% 
DMSO. Positive controls in duplicate wells were cultured with 
10 µg/ml phytohemagglutinin (Sigma-Aldrich, Dorset, UK) and 
a pool of CMVpp65-peptides. Each individual HIV and CMV 
peptide was at a final assay concentration of 1.5 µg/ml. PBMCs 
were thawed and rested overnight in RPMI 20% HIFCS prior to 
ELISpot assay setup. On the day of assay setup, viable PBMCs 
were counted using a Beckman Coulter Vi-cell XR counter and 
plated at 2 × 105 cells/well in 50 µl and incubated for 16–24 h 
at 37°C, in 5% CO2. Spots were visualized using biotinylated 
anti-IFN-γ (Mabtech) combined with ABC streptavidin-HRP 
(Vector labs), and the color was developed using AEC substrate 
(Sigma). The reaction was stopped after 4 min by rinsing with 
tap water.
Plates were air dried overnight and the spots counted using 
an AID ELISpot Reader and version 5.0 software (AID GmbH). 
After quality control of the data, the mean number of spot forming 
units (SFU) in no-peptide wells was subtracted from test wells, 
and the results were expressed as the median net SFU/106 PBMC. 
Responses at least 38 SFU/106 PBMCs above background and 
at least 4× background were scored as positive. These response 
cutoffs were derived from assessing the 97.5% percentile of the 
peptide pool responses in PBMC from 95 HIV seronegative 
individuals.
intracellular Cytokine Staining and 
analysis
To characterize T follicular helper cell responses, study samples 
at 2 weeks after the third priming injection and after the respec-
tive booster injection along with matched baseline samples 
were interrogated for phenotype and cytokine secretion using 
cross-qualified polychromatic flow cytometry. Cryopreserved 
PBMCs were thawed and rested overnight and resuspended at 
1 ×  106 in 200  µl RPMI medium supplemented with 10% FBS 
and co-incubated with HIV-peptide pools, 1  μg/ml staphylo-
coccal enterotoxin B (Sigma-Aldrich, Poole, Dorset, UK) or 
mock stimuli, BD Golgistop (Becton Dickinson, San Jose, CA, 
USA) and Brefeldin A (Sigma-Aldrich, Poole Dorset, UK) 
for 6  h at 37°C. Cells were stained with 50  µl LIVE/DEAD 
fixable aqua viability dye L34957 (Invitrogen, Paisley, UK), 
anti-CD4-V605 (Biolegend, UK), anti-CD45RO-PerCP-Cy5.5, 
anti-CXCR5-A488, anti-CXCR3-PeCF594, anti-PD-1-BV421, 
and anti-CCR7-PE-Cy7 (Bec ton, Dickinson, Oxford, UK) and 
stained intracellularly with anti-CD154-PE and anti-IFN-γ-APC 
(Becton, Dickinson, Oxford, UK) (see Table S5 in Supplementary 
Material). A mini mum of 30,000 viable CD3+ CD4+ lymphocyte 
events were acquired on a BD LSR Fortessa, which had been set 
up according to the Perfetto protocol (34, 35). Data were analyzed 
using FlowJo (Treestar, Ashland, OR, USA), PESTLE, and SPICE 
(courtesy of Mario Roederer, Vaccine Research Center, National 
Institutes of Allergy and Infectious Diseases) software. An intra-
cellular cytokine secretion responder was considered positive if 
the background-subtracted values were twice those of the mock 
stimulus for each CD4-cytokine combination.
mBC Stimulation
To assess the magnitude of mBC responses, we adapted a pre-
viously published protocol (36). In brief, frozen PBMC from 
baseline (D0), 28  days post-priming phase (D84) and 28  days 
post-booster injection (D196 or D364) were resuspended at 
1 × 106 PBMC/ml in stimulation media composed of R10, 5 ng/ml 
IL-2 (Roche, UK) and 0.5 µg/ml R848 (Vac-r848, Invivogen, UK), 
cultured for 4 days and washed with R10 prior to plating.
B-Cell eliSpot
Sterile 96-well ELISpot plates (MSIPS4510 from Millipore) were 
pre-wet with 15 μl/well 70% EtOH for 1 min. After washing the 
plates five times with 200 μl/well sterile water, 100 μl/well of the 
CN54gp140 Ag (5  µg/ml) and 100  µl of the capture antibody 
MT91/145 (Mabtech, at 15  µg/ml) were added to the ELISpot 
plate and incubated overnight at 4°C. To remove excess Ag, plates 
were washed five times with sterile 200 μl/well PBS before block-
ing with 200 μl/well R10 for 1–2 h, at 4°C. Following the removal 
of R10, cells were added at 10,000/well for total IgG and 125,000/
well for Ag-specific response in R10. Each condition was tested in 
triplicate, and plates were incubated for 6 h at 37°C, 5% CO2. For 
spot development, plates were first washed six times with 200 μl/
well PBS and then 100 μl/well of detection antibody MT78/145 
(Mabtech, 1:500) was added at 1 µg/ml in PBS/0.5% FCS and incu-
bated overnight at 4°C. The next day plates were washed five times 
with 200 μl/well PBS and 100 μl/well streptavidin-HRP (Mabtech, 
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1:1,000), diluted in PBS/0.5% FCS, was added and incubated for 
1 h at room temperature. Fifteen minutes before developing the 
plate, the AEC substrate (BD Biosciences) was prepared accord-
ing to the manufacturer’s instructions. After washing the plates 
five times with 200 μl/well PBS, 100 μl/well of the AEC substrate 
solution was added and incubated for a maximum of 5–10 min 
before stopping the spot development with tap water. SFU were 
counted using an automated AID ELISpot reader (Autoimmun 
Diagnostika GmbH, Strassberg, Germany).
Customized Multiplex Dimer assay
A customized multivariate multiplex assay was developed using 
a panel of gp140 Ags (Clade C: CN54, 1086, Clade A: UG37, 
Clade D: UG21–NIH AIDS Reagents) coupled to magnetic fluo-
rescent multiplex beads (Bio-Rad, AU) as described previously 
(37). Biotinylated dimeric Fc-gamma-receptors (FcγRIIa-H131, 
FcγRIIIa-V158) were produced as previously described (16).
Coupled microspheres were premixed in multiplex assay 
buffer (PBS +  0.1% BSA +  0.05% Tween), creating a working 
mixture of 12.5 microspheres/bead type/μl. Using a black, clear 
bottom 96-well plate 40 µl of the working microsphere mixture 
(1,000 beads of each type/well) was added to 40 µl of 100× diluted 
serum (diluted in PBS). The plate was covered and incubated 
overnight at 4°C on a plate shaker. The plate was washed three 
times with 200 µl of assay wash (PBS-1×, 0.1% BSA, 0.5% Triton-
100X) using a Bio-Plex Pro plate wash station (Bio-Rad, AU). 
Ag-specific antibody binding to dimeric FcγRs was detected 
by adding FcγRs followed by streptavidin PE, at 1.0 µg/ml with 
50 μl/well. After 2 h incubation at room temperature on a shaker, 
the plate was washed three times with 200 µl of assay wash, and 
microspheres were resuspended in 100 µl of sheath fluid.
A Bio-Plex reader (Bio-Plex MAGPIX, Bio-Plex Manager 5.0, 
Bio-Rad) was used to detect the microspheres, and binding of 
PE was measured to calculate a median fluorescence intensity 
(MFI). Background signal, defined as the average MFI observed 
for each microsphere set when incubated with the PE-conjugated 
detection reagent in the absence of clinical antibody sample, was 
subtracted from the MFI for each sample.
HiV neutralization
Sera were tested for neutralizing activity against HIV-1 at 
Monogram Biosciences (San Francisco, CA, USA) as described 
previously (38, 39). A panel of viruses (92BR020, 92TH021_043, 
93IN905_040, 94UG103_023, MGRM-C-026_024, SF162, 
TH023) covering clades A, B, C, E, and including the neutrali-
zation sensitive laboratory strain NL43 and the primary isolate 
JRCSF, was used. Neutralizing activity is displayed as the percent 
inhibition of viral replication (luciferase activity) at each antibody 
dilution compared with the specificity control (aMLV). Titers 
were calculated as the reciprocal of the plasma dilution confer-
ring 50% inhibition (IC50).
Statistical Methods
Statistical analysis was carried out using Prism 7.0a (GraphPad, 
CA, USA) or the R software (R3.3.2) for statistical program-
ming (40).
reSUlTS
Sequential intramuscular injections of the 
Clade C enV Protein Cn54gp140 appear 
Safe in Healthy adult Volunteers
Fifteen study volunteers were assessed for eligibility with 14 
deemed eligible according to the pre-defined inclusion and 
exclusion criteria. Two participants in study Group A withdrew 
due to personal reasons and were not included in the final immu-
nogenicity analysis (Figure 1).
The majority of participants were male, and the mean age was 
27.2  years (Table S1 in Supplementary Material). Overall, the 
vaccine was safe and well tolerated. Table S2 in Supplementary 
Material shows the proportion of volunteers with Grade 2 or 
higher reactogenicity events through day 7 post any vaccination. 
Most systemic reactogenicity events (fever, malaise, myalgia, 
headache, nausea, and vomiting) were graded as Grade 1 or 
Grade 2. The overall frequency of any Grade 2 or higher systemic 
reactogenicity following any vaccination was 42.9% (95% CI: 
17.7–71.1; Table S2 in Supplementary Material). One Group B 
volunteer, X00143007, reported Grade 3 malaise on Day 2 after 
the third vaccination. All other reactions were Grade 1 or Grade 
2 among volunteers in both study groups. All local reactogenicity 
(pain, tenderness, erythema/skin discoloration, and swelling/
hardening or thickening) were graded as present or Grade 1.
Systemic Vaccine-induced Humoral 
response
The humoral response to two homologous prime-boost HIV- 
vaccine regimens (Group A, n = 6; Group B, n = 5) was initially 
assessed by Ag-specific ELISA before and after sequ ential intram-
uscular IMs with the clade C ENV protein CN54gp140 (Figure 2). 
A low responder in Group B (Figure S3 in Supplementary Material) 
with significantly reduced levels of Ag-specific antibody levels 
was excluded as an outlier from the immunogenicity analysis in 
Figure 2.
The initial priming phase (first three IMs, Table 1) was com-
mon to both groups. Ag-specific IgG, IgA, and IgM antibodies 
were detected as early as 14 days after the first priming IM in both 
groups. IgG responses were significantly higher than IgA and 
IgM responses (p < 0.0001, Group A and B). Peak Ag-specific 
IgG, IgA, and IgM levels were reached after second IM, while 
the third IM had little additional impact on the magnitude of 
the response (Figures  2A,B). The decay in Ag-specific levels 
(IgG and IgA) between days 84 and 168 was similar for both 
groups (Group A/B: 2.4-fold/3.4-fold for IgG and 3-fold/3.7-
fold for IgA). Although IgM levels appeared lower at day 168 in 
group B relative to group A, the differences were not statistically 
significant (p > 0.9999), where levels for both groups were at the 
lower limits of detection. In the boosting phase the fourth IM 
at 6 months (Group A) and 12 months (Group B) had a similar 
impact on the magnitude of boosted responses with no statisti-
cal differences between the respective endpoints of Ag-specific 
IgG, IgA, and IgM (Group A versus Group B: IgG: p > 0.99, IgA: 
p > 0.99, IgM: p = 0.56).
FiGUre 1 | COnSOrT Flow diagram. Numbers of participants recruited into the trial. Fifteen individuals were screened for the study, 14 were enrolled into the 
study (8 were enrolled into Group A, 6 into Group B), and 13 volunteers received all four intramuscular immunizations.
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Further subclass analysis was performed to dissect IgG-
subclass responses. Ag-specific IgG1/2/3 were detected as early 
as 14 days after the first IM on D0 (Figures 2C,D). Ag-specific 
IgG1/2 antibodies dominated the antibody profile in both 
groups and were detectable across all visits 14 days post the first 
IM. Interestingly, while the third IM had no apparent impact 
on Ag-specific IgG1/2 levels, it induced Ag-specific IgG4 levels 
in both groups, and these continued to rise between days 84 
and 168 (Figures 2C,D) and were significantly boosted by the 
respective fourth IM (Figure S4 in Supplementary Material). In 
contrast, concentrations of Ag-specific IgG3 rapidly declined 
after the third IM to below the detection limit of the assay 
but were re-boosted to similar levels following the fourth IM 
(D168, Group A and D336, Group B). Intriguingly Ag-specific 
IgG2 levels appeared to be better sustained over days 84–168 
in both groups than IgG1, which decayed 4.3-fold (Group 
A)/6.9-fold (Group B) and was of similar magnitude to IgG2 
by day 168 in Group A (Figure  2C; IgG1/IgG2 ratio =  1.4), 
dropping below the levels of Ag-specific IgG2 by day 336 in 
group B (Figure  2D; IgG1/IgG2 ratio =  0.2). There was no 
apparent difference in Ag-specific IgG-subclass response to 
early (6  months, Group A) and late (12  months, Group B) 
boosting IMs (fourth IM); however, these re-boosted levels 
of Ag-specific IgG in both groups to levels observed after the 
second IM.
Mucosal ag-Specific antibody levels 
Directly reflect Systemic responses
Antigen-specific mucosal antibody levels were determined using 
optimized sampling protocols and a high sensitivity ELISA assay. 
Reference values for total IgG and IgA for the different mucosal 
secretions are given in Figure S5 in Supplementary Material. 
Low levels of Ag-specific IgG antibodies could be detected 
in seminal and rectal secretions (Figure  3) and, for the four 
FiGUre 2 | antigen (ag)-specific humoral responses in human serum samples following homologous prime-boost vaccination regimens. Participants 
received 3× priming immunizations (IMs) of CN54gp140 adjuvanted with GLA-AF on days 0, 28, and 56, followed by a booster injection at day 168 (Group A) or day 
336 (Group B). Indicated by dotted line and numbers 1°–4°. (a,B) CN54gp140-specific IgG, IgA, IgM and (C,D) IgG-subclass concentrations were measured in 
human serum/plasma and expressed as mean ± SEM. (e) The sum of the four IgG subclasses was calculated and used to determine the percentage of 
CN54gp140-specific IgG-subclass antibodies 14 days after the priming phase (D70) and 14 days after the respective booster injections (D182/D350) for both 
Groups A and B. The proportion of Ag-specific IgG1 was decreased, while Ag-specific IgG4 levels were significantly increased after the respective booster IMs. 
Non-parametric Mann–Whitney test (*p < 0.05, **p < 0.01).
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female participants, in cervicovaginal secretions (Figure S6 in 
Supplementary Material).
Mucosal antibody levels were significantly lower than Ag- 
specific IgG in serum samples (Figures 3A–D), but significantly 
correlated (p < 0.0001) with Ag-specific IgG in serum samples 
from both groups (Figure  3E). Response curves in mucosal 
secretions and the systemic compartments were identical, with 
a relatively constant differential between mucosal and systemic 
antibody levels between the respective compartments in both 
study groups (Figures 3A–D). Comparable trends were observed 
for both Groups A and B (Figures 3A–D) with no statistical dif-
ference in peak Ag-specific mucosal antibody levels 2 weeks post 
the fourth IM. Ag-specific IgG was below the limit of detection 
in urethral samples and reflects the low level of detected total 
IgG (Figure S5 in Supplementary Material) by this method. None 
of the mucosal samples exhibited detectable levels of Ag-specific 
IgA (data not shown), reflective of the low serum IgA responses 
(Figure 2).
Vaccine-induced antibodies Target the V3 
region of the Clade C Cn54gp140 enV 
Protein
Vaccine-induced IgG responses toward linear epitopes in the 
HIV Env were mapped using a customized peptide microarray 
consisting of overlapping linear 15mer Env peptides 2 weeks after 
third and fourth IM in relation to baseline (Figure 4).
Both groups, irrespective of the interval between booster 
injections, showed similar IgG Env-peptide recognition patterns 
(Figure 4A) both before and after the fourth IM. No difference 
in epitope recognition between the two groups was observed. A 
dominant recognition of the V3 tip region (peak number 2) by all 
FiGUre 3 | antigen (ag)-specific humoral responses in seminal and rectal secretions following homologous prime-boost immunization (iM). 
Participants received 3× priming IMs of CN54gp140 adjuvanted with GLA-AF on days 0, 28, and 56, followed by a booster injection at day 168 (Group A) or day 
336 (Group B); indicated by dotted line and numbers 1°–4°. (a–D) CN54gp140-specific IgG was measured in human serum/plasma, seminal (n = 8) and rectal 
secretions (n = 11) and expressed as mean ± SEM. (e) Ag-specific IgG levels in seminal secretions correlate significantly with systemic IgG in both groups, while 
correlation coefficients (r-values) were lower when comparing Ag-specific IgG in rectal and systemic compartments. Spearman’s rank correlation coefficient 
(p < 0.0001).
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vaccines can be observed after the three priming IMs. The longer 
boosting interval (Group B) was associated with an apparently 
higher median response to the V3 tip when compared to Group 
A. This difference, however, was not significant due to the high 
inter-individual variation in the IgG response toward the V3 tip 
(Figure S7 in Supplementary Material). IgG responses toward 
other regions within gp120 (peaks number 1 and 3, Figure 4B) 
were of lower magnitude and observed with varying frequency 
(33–83% of all vaccines) at both time points and in both groups. 
Recognition of gp41 only seems to occur in Group A, albeit 
already after three IMs and therefore seems to be due to interin-
dividual differences in the IgG response rather than attributable 
to the boosting interval. There were no significant differences 
between the two groups in the total sum of fluorescence intensity 
values for all peptide variants included in the array (Figure 4C).
Comparison of Fc-receptor Binding 
Characteristics of Cn54gp140-Vaccine-
induced Serum antibodies between Study 
Groups
Even though vaccine-elicited antibodies did not neutralize virus 
in this study (Table S3 in Supplementary Material), we sought to 
further investigate the ability of Ag-specific antibodies to cross-
link Fc receptors. Recently, the role of non-neutralizing HIV anti-
bodies in vaccine-mediated protection has gained prominence as 
they can induce important Fc effector-mediated functions. We 
have previously developed an assay using recombinant dimeric Fc 
receptors that provide an indirect readout for influenza-specific 
ADCC and phagocytosis (15, 16). Here, we investigated any 
differences in the ability of vaccine-induced serum antibodies to 
interact with dimeric Fc receptors FcγRIIIa and/or FcγRIIa after 
binding to various HIV-1 clade env proteins (Figures S8–S10 in 
Supplementary Material). For C.CN54gp140, A.UG37gp140, 
or D.UG21 proteins, both FcγR-profiles (Figures  5A–D) and 
Ag-specific IgG levels were compared (Figures 5E,F).
In both groups, clade C and D binding vaccine-induced anti-
bodies were detected by the dimeric FcγRIIIa and FcγRIIa, while 
vaccine-induced antibodies specific to clade A did not crosslink 
dimeric FcγRIIIa and FcγRIIa (Figures 5A–D).
As expected, in an Ag-specific ELISA the largest proportion 
of vaccine-induced antibodies bound the clade C CN54gp140 
immunogen (Figures  5E,F). Fourteen days after the final IM 
(Figures  5E,F, indicated by 4°), the concentration of vaccine-
induced antibodies binding to clade A and/or clade D was about 
3- or 4.5-fold lower, respectively, in Group A and 2- or 5-fold 
FiGUre 4 | Peptide array analysis of env-specific igG responses. (a,B) Specificity of serum IgG responses at 14 days after the third and fourth intramuscular 
immunization (IM) for Group A and B. Shown is the median fluorescence intensity (MFI). IgG responses against individual antigenic regions were considered positive 
if the corresponding fluorescence intensity was above 2,500 after subtraction of the prevaccination value (D0). The MFI was then calculated for region-specific IgG 
responses occurring in at least 25% of vaccines. (C) Comparison of total fluorescence intensity of ENV-specific serum antibodies 4 days post third/fourth IM for 
Group A and B showed no significant differences (Mann–Whitney test).
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lower, respectively, in Group B (Figures 5E,F). Overall, the fin-
gerprint of Fc-receptor binding, associated with different HIV-1 
clades, was similar in both pattern and magnitude for the two 
study groups (Figure  5; Figure S7 in Supplementary Material) 
and FcR engagement following binding to five HIV-clade pro-
teins correlated significantly with levels of CN54gp140-specific 
IgG1, 2 and 3 in both groups (Figure 6). Similarly to a previous 
study of HIV-controllers (41), the strongest positive correlation 
with nearly identical spearman coefficients between Group 
A and B was observed between FcγRIIIa/FcγRIIa dimeriza-
tion and CN54gp140-specific IgG1 (Group A/B: ***p <  0.001, 
***p < 0.001). The increases after the initial IM and subsequent 
declines observed in the Ab response profiles (Figures 5E,F) for 
the two groups are generally matched as features in the FcR activ-
ity profiles (Figures 5A–D). Interestingly, however, FcγR activity 
was not merely reflective of Ab titer since, the dimeric FcγRIIIa 
showed similar binding activity to opsonized clade C and clade D 
(Figures 5A,B), despite a profound reduction in antibody detect-
ing clade D HIV Env (Figures 5E,F). Significantly, this suggests 
the antibodies that did cross-react against clade D Env, though 
low in titer, had high Fc-receptor binding ability.
Both Prime-Boost regimens induced 
ag-Specific mBC responses in the 
absence of Detectable T Cell responses
An mBC ELISPOT assay was used to compare the dynamics 
and magnitude of Ag-specific mBC responses, generated by the 
two homologous prime-boost HIV-vaccine regimens (Group A, 
n = 6; Group B, n = 5) at 28 days after the third and fourth IM, 
respectively (Figure 7).
The frequency (mean ±  SD) of Ag-specific mBC responses 
was similar for both vaccine regimens at 28 days after the third 
priming IM (Group A: 0.37 ± 0.25%; Group B: 0.21 ± 0.19%) and 
28 days after the fourth IM (Group A: 0.47 ± 0.29%; Group B: 
0.57 ± 0.46%). In each group, the highest responders exhibited 
an Ag-specific mBC frequency of about 1% total IgG-positive 
mBC. In contrast to the mBC response, no positive Ag-specific 
FiGUre 5 | Fcγr-binding profiles and breadth of antigen (ag)-specific humoral responses in serum samples following homologous prime-boost 
immunization. The ability of vaccine-induced antibodies recognizing clade C.CN54gp140, A.UG37gp140, and D.UG21gp140 human immunodeficiency virus (HIV) 
proteins to bind dimeric (a,B) FcγRIIIa or (C,D) FcγRIIa was assessed in a customized multiplex dimer assay. (e,F) For further comparison, HIV-binding antibodies 
(e,F) were determined for the three selected clades for both study groups (A, n = 6 and B, n = 5).
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T cell responses were detected, via IFNγ-ELISpot or intracellular 
staining for CD154 and IFNγ, 14 days after the third and fourth 
IM in either group (Figure S11 in Supplementary Material).
DiSCUSSiOn
The empirical process of optimizing IM schedules is likely key to 
the development of an efficacious HIV vaccine, where the interval 
between sequential IMs can prove critical in shaping the matura-
tion of the induced adaptive immune response (42). This study 
was designed to analyze the effect of alternate booster regimens 
on antibody response profiles to CN54gp140 adjuvanted with 
GLA-AF. Study participants received a common three-dose 
intramuscular priming series followed by a final booster at either 
6 or 12  months. Similar to previous studies (26, 27, 33), both 
regimens were observed to be safe and well tolerated, providing 
further evidence that CN54gp140-based vaccines exhibit a good 
safety profile.
The three initial doses of CN54gp140 were given at minimal 
intervals of 4  weeks and were anticipated to induce successive 
FiGUre 6 | Correlations between Cn54gp140-specific igG subclass measurements and Fcγriia (CD32a)/Fcγriiia (CD16a) binding profiles for Group 
a and B. A customized multiplex assay was used to determine binding of dimerized FcγRIIa or FcγRIII following binding to different human immunodeficiency virus 
(HIV)-clade proteins in serum samples from Group A and B. For simplicity, the horizontal and vertical labels, indicating the various HIV-clade proteins, were labeled 
with the ending .2a or .3a, respectively, to designate FcγR dimers. Correlations between CN54gp140-specific IgG subclasses are boxed in red, and correlations 
between FcγRIIa/FcγRIIIa binding profiles are boxed in blue, while correlations directly related to the CN54gp140 antigen, which was used for serial immunizations, 
are boxed in green. C.CN54gp140-mediated engagement of both FcγRII- and FcγRIIIa-receptors was positively associated with CN54gp140-specific IgG1/2 in both 
groups. Both study groups exhibit identical isotypic and FcγR-binding profiles. rS—Spearman’s rank correlation coefficient (*p < 0.05, **p < 0.01, ***p < 0.001).
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waves of Ag-specific antibody responses, where multiple admin-
istrations of protein vaccines are generally assumed to increase the 
magnitude of both T cell and antibody responses (43). In this study, 
peak IgG binding titers were reached following two priming IMs 
(at 0 and 28 days), while the administration of a third dose had no 
additional impact on the magnitude of Ag-specific IgG antibody 
titer. These data strongly suggest that two intramuscular priming 
doses are likely sufficient to induce strong antibody responses 
FiGUre 7 | analysis of the memory B cell (mBC) response induced by sequential immunization with the human immunodeficiency virus-antigen 
Cn54gp140. Frozen peripheral blood mononuclear cells (PBMCs) were thawed and expanded using human IL-2 and R848 for 4 days. Expanded cells were 
assayed for antigen (Ag)-specific and total IgG-secreting ASCs by ELISPOT assay at 0, 84, and 196 or 364 days, respectively. Each sample was measured in 
triplicate, averaged and plotted as Ag-specific per total mBC. (a) Percentage of Ag-specific mBC per total IgG-secreting mBC. Due to the limitation in availability of 
PBMC at least one data point is missing for the following participants: S001 (D0), S002 (D0), and S013 (D0 and D196). (B) Ag-specific spot forming units/well 
(indicated by lower indices) Ag-specific mBC and total-IgG-secreting mBC for one selected donor from each group for days 0, 84, and 196 or 364, respectively.
13
Kratochvil et al. CN54gp140 Prime-Boost Interval Study
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 595
against CN54gp140. In this respect, previous studies using 
influenza hemagglutinin as an immunogen have indicated that 
the spacing between the first and second priming IM is similarly 
effective when administered at 14 rather than 28 days but is less 
efficient when this interval is reduced to 7 days (44). However, it 
has been suggested that a wider interval of 2 or 3 months between 
sequential IMs may be optimal to maximize the induction of a 
memory response (43). Interestingly, when using heamagglutinin 
as an Ag, the magnitude and breadth of the humoral response was 
increased by delaying the second priming dose to 6 months (44). 
Further studies are needed to identify the optimal timing of sec-
ondary administration of CN54gp140 to maximize the efficiency 
of two homologous priming injections. Furthermore, while the 
third priming IM had no apparent effect on the magnitude of 
induced binding antibody titers, we cannot exclude that this 
may have had an adverse impact on the durability of the induced 
antibody response. Indeed, previous studies using gp120 as an 
immunogen have suggested that repeated short-interval dosing 
reduced the durability of induced Ag-specific antibody levels 
(45). The possibility of dropping the third redundant priming IM 
has the potential to improve the durability of induced response 
warrants further investigation.
The common priming phase induced strong serological 
CN54gp140-specific IgG responses. These were mirrored by IgA 
and IgM responses in sera that were approximately two logs lower. 
IgG subclass analysis revealed a hierarchy in isotype responses 
where IgG1>IgG2>IgG3 with approximately a 1-log difference 
between each. The observed levels of IgG2 were higher than those 
reported for gp120 adjuvanted with alum in the Vax (003, 004) 
trials and in the RV144 trial (46), and likely reflect the adjuvant 
effects of GLA-AF inducing a Th1 biased profile (47). Importantly, 
using our optimized ELISAs, we were able to document IgG1–4 
responses in all participants, whereas IgG2–3 responses were 
detected less frequently in the RV144 and VAX004 studies (46). 
Notably in our study, Ag-specific IgG4 only emerged after the 
third IM, in line with the known induction of IgG4 in response 
to repetitive Ag exposure and reflective of responses in VAX003 
(46). Interestingly, despite having identical half-lives of 21 days 
(11), induced IgG2 levels appeared to have a slower decay rate to 
IgG1 between the priming phase and boosting in both groups. 
The mechanisms governing the different decay patterns could 
provide important insights into the mechanisms governing the 
longevity of induced humoral immunity.
A main focus of our study was to determine the impact of a long 
interval between the priming and boosting phase of vaccination. 
As previous studies using gp120 as an immunogen had indicated 
that boosting at 6 months was superior to that at 4 months (48), 
we elected to compare the response between booster IMs admin-
istered at 6 months (standard) or 12 months (late). We found no 
evidence to support that a long resting phase (12 months) had any 
impact on the magnitude of induced responses over the standard 
regime (6  months). IgG binding antibody levels post boosting 
were restored to similar levels to that observed after the priming 
phase but were not further increased. In contrast to our findings, 
a previous study using gp160 as an immunogen, adjuvanted with 
alum, and with a priming phase of 0, 1, and 6 months, reported 
that a delayed booster given at 18  months increased the mag-
nitude of induced binding antibodies (49). However, responses 
were relatively low after the first three IMs in the latter study and 
likely reflect differences in the adjuvant potential of GLA-AF and 
alum.
We observed that for most antibody isotypes there was no 
apparent difference in Ag-specific antibody levels after the stand-
ard or late booster (total specific IgG, IgA, IgM, IgG1, and IgG3). 
However, Ag-specific IgG4 increased significantly in both groups 
after the final booster. Notably, this increase in IgG4 was not 
accompanied by a decline in IgG3 binding antibodies as reported 
for VAX003 (46). Analogous to previous HIV-vaccine studies our 
results link the late emergence of Ag-specific IgG4 antibodies with 
responses to repetitive boosting (46). This late emergence of IgG4 
antibodies following repeated Ag exposure has been linked to the 
terminal position of the Cγ4 cassette (11, 50). Interestingly, we 
also observed an increase in IgG2 binding antibodies following 
boosting in both groups altering the relative IgG subtype propor-
tions relative to those observed post third IM (Figure 2). The role 
of IgG2 in HIV immunity is unclear (9). Typically, IgG2 responses 
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are more common against carbohydrate epitopes (11, 51) and 
may be better suited for the induction of anti-glycan responses 
associated with neutralization (although not observed here). Both 
IgG2 and IgA responses appear to be suppressed in HIV infection 
mediated by HIV nef, suggesting that this is a potential immune 
evasion mechanism (52). However, like IgG4, IgG2 is a poor 
activator of FcR engagement and thus poor at triggering ADCP 
and ADCC relative to IgG1 and IgG3 (46, 53, 54). It is unclear 
if the observed increase in IgG2 levels following the fourth IM 
would be further increased with additional boosters. In any event, 
the data provide another example that vaccine-induced immune 
responses are rarely static and have the potential to be modulated 
where additional boosters may be required to maintain protective 
antibody levels.
To further evaluate the quality of antibody responses, we used 
FcγRIIIa/FcγRIIa ectodomains to probe vaccine-induced serum 
IgG for its ability to engage Fc receptors critical to cellular func-
tions such as ADCC or ADP (16). The importance of ADCC has 
been highlighted by the RV144 trial, in which robust HIV-specific 
ADCC responses were linked to the observed partial protection 
(7, 55, 56). In this study, we identified identical FcγR-binding 
profiles between the two study groups and found that both vac-
cine regimens induced comparable levels of Abs specific to both 
the clade C immunogen and a heterologous clade D Env protein 
capable of binding dimeric FcγRIIIa/FcγRIIa receptors. There 
was a relative robust ability of the cross-reactive antibodies to 
the clade D Env to bind both FcγRIIIa/FcγRIIa receptors despite 
very low binding antibody levels, suggesting these cross-reactive 
antibodies had a high capacity for binding Fcγ receptors. Cross-
reactive binding Abs specific to clade A, however, were low and 
did not crosslink either Fc-receptor dimer. It is possible that the 
binding of vaccine-induced serum IgG to clade A was too transient 
for the detection of FcγR ectodomain engagement. Interestingly, 
the levels of FcγRIIIa/FcγRIIa receptor aggregation were similar 
post-boost in both groups, despite increasing levels of IgG2 and 
IgG4 (Figure 2). This contrasts to a previous analysis of VAX003 
where boosting was associated with a drop in ADCC and ADCP 
function. The difference between the latter study and our own 
is that IgG3 binding antibody levels were similar post third and 
fourth IM, whereas in VAX003 IgG3 levels were decreased on 
boosting together with a concomitant rise in IgG4 level (46).
Complementary peptide array analysis revealed that most 
vaccine-induced IgG antibodies were specific to the V3 tip region 
with no significant differences between alternate boosting inter-
vals. Despite the high prevalence of binding antibodies against 
CN54gp140 in both groups, we observed minimal neutralizing 
antibody responses against a panel of tier 1 HIV isolates, in line 
with our previous studies (26, 27, 33). Interestingly, both regi-
mens also induced non-neutralizing binding antibodies against 
clade C and D and other envelope proteins. The demonstration 
of CN54gp140-mediated multi-clade specificity further expands 
the scope of CN54gp140-associated immune responses, as this 
was not examined in our previous clinical trials (26, 27, 33). The 
induction of strong antibody responses against the Env immuno-
gen CN54gp140 is assumed to be dependent on Ag-specific T fol-
licular helper cells. While both study regimens induced detectable 
Ag-specific mBC responses in the periphery, we did not detect 
systemic CD4 T-cell responses. This likely reflects that B cell help, 
provided by T follicular helper cells, is largely restricted to the 
GCs, whereas the frequency of circulating vaccine-induced Tfh 
cells is low and difficult to detect (57, 58). Recent studies have sug-
gested that lymph node (LN) fine-needle aspirates may provide 
a more accurate assessment of vaccine-induced Tfh responses 
(59, 60). Direct probing of draining LNs could be especially useful 
to better understand how the circulation of GC B and T cells leads 
to the generation of specific and broader immune responses to 
gp140 immunogens.
In this study, mucosal samples were used to assess antibody 
levels in vaginal, genitourinary, and anorectal compartments. 
Encouraged by our previous findings (27), we developed 
more sensitive assays and subsequently identified a significant 
correlation between Ag-specific IgG response curves in the 
systemic and mucosal compartments. These highly similar 
profiles provide strong evidence that the frequency of seminal, 
rectal, and vaginal antibodies is reflective of the transudation 
of systemic antibodies to the mucosae. This passive transuda-
tion, occurred irrespective of the booster regimen, and supports 
the hypothesis that the induction of strong systemic responses 
via vaccination can elicit detectable antibody levels at mucosal 
surfaces. In this respect, mucosal antibody levels may provide 
an important surrogate of mucosal tissue levels, providing a 
key defense against HIV acquisition (61). The low magnitude of 
mucosal Ag-specific IgA directly reflects the low systemic levels 
of detectable Ag-specific IgA.
In summary, we applied innovative immunoassays to directly 
compare the effect of alternately timed booster regimens on the 
maturation of vaccine-induced humoral responses. The dissec-
tion of immuno-fingerprints of both booster regimens not only 
demonstrated that diverse Ag-specific HIV-1 humoral responses 
were effectively and safely induced but also revealed strikingly 
similar correlations between vaccine-induced IgG-subclass anti-
bodies and Fc-receptor engagement between the two homologous 
prime-boost vaccine regimens. The significant similarities in 
response magnitude and antibody profiles, associated with both 
IM schedules, strongly support the feasibility of adopting the 
accelerated 6-month regimen for the rapid induction of immune 
responses against CN54gp140 with no apparent risk of diminish-
ing response strength or Fc-receptor binding ability.
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